Quality of life in patients with COPD: Quantification criteria and therapeutic repercussions;La calidad de vida en los pacientes con enfermedad pulmonar obstructiva crónica: Criterios de cuantificación y repercusiones terapéuticas

Revista Clinica Espanola

Volumn 205, Issue 9, 2005, Pages 439-442

  Miravitlles, Marc ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; IMMUNOFERON; INTERLEUKIN 8 ANTIBODY; MONOCLONAL ANTIBODY; SALMETEROL; TIOTROPIUM BROMIDE;

AIRWAY OBSTRUCTION; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORRELATION ANALYSIS; DEVELOPED COUNTRY; HEALTH STATUS; HUMAN; PREVALENCE; PROGNOSIS; QUALITY OF LIFE; RESPIRATORY AIRFLOW;

EID: 27744531610     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1157/13079073     Document Type: Article

References (27)

1. Sobradillo V, Miravitlles M, Gabriel R, Jiménez-Ruiz CA, Villasante C, Masa JF, et al. Geographical variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study. Chest. 2000;118:981-9.
2. Miravitlles M, Murio C, Guerrero T, Gisbert R on behalf of the DAFNE study group. Costs of chronic bronchitis and COPD. A one year follow-up study. Chest. 2003;123:784-91.
3. Cerveri I, Accordini S, Verlato G, Corsico A, Zoia MC, Casali L, et al. Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults. Eur Respir J. 2001;18:85-92.
4. Celli BR, Cote CG, Marín JM, Casanova C, Montes de Oca M, Méndez RA, et al. The body-mass index, airflow obstruction, dyspnea, and excercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350:1005-12.
5. Engström CP, Persson LO, Larsson S, Sullivan M. Health-related quality of life in COPD: why both disease-specific and generic measures should be used. Eur Respir. J. 2001;18:69-76.
6. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax. 2001;56:880-7.
7. Doll H, Miravitlles M. Quality of life in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature. Pharmacoeconomics. 2005;23:345-63.
8. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. Am Rev Respir Dis. 1992;145:1321-7.
9. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J. 2002;19:398-404.
10. Guyatt GH, Berman LB, Towsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987;42:773-8.
11. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol. 1994;47:81-7.
12. Osman LM, Godden DJ, Friend JAR, Legge JS, Douglas JG. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax. 1997;52:67-71.
13. Miravitlles M, Ferrer M, Pont A, Zalacain R, Álvarez-Sala JL, Masa JF, et al, for the IMPAC study group. Exacerbations impair quality of life in patients with chronic obstructive pulmonary disease. A two-year follow-up study. Thorax. 2004;59:387-95.
14. Andersson I, Johansson K, Larsson S, Pehrsson K. Long-term oxygen therapy and quality of life in elderly patients hospitalised due to severe exacerbation of COPD. A 1 year follow-up study. Respir Med. 2002;96:944-9.
15. Fan VS, Curtis JR, Tu SP, McDonell MB, Fihn SD for the Ambulatory Care Quality Improvement Project Investigators. Using quality of life to predict hospitalization and mortality in patients with obstructive lung diseases. Chest. 2002;122:429-36.
16. Domingo-Salvany A, Lamarca R, Ferrer M, García-Aymerich J, Alonso J, Félez M, et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166:680-5.
17. Miravitlles M, Álvarez-Sala JL, Lamarca R, Ferrer M, Masa F, Verea H, et al for the IMPAC study group. Treatment and quality of life in patients with chronic obstructive pulmonary disease. Qual Life Res. 2002;11:329-38.
18. Miravitlles M. Nuevos tratamientos de la enfermedad pulmonar obstructiva crónica. Med Clin. En prensa 2005.
19. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Ikeda A, et al. Health status measured with the CRQ does not predict mortality in COPD. Eur Respir J. 2002;20:1147-51.
20. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med. 1997;155:1283-9.
21. Dahl R, Greefhorts LAPM, Nowak D, Nonikov V, Byrne AM, Thompson MH, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 164:778-84.
22. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following six months treatment with once daily tiotropium compared to twice daily salmeterol in patients with COPD. Thorax. 2003; 58:399-404.
23. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320:1297-303.
24. Calverley P, Pawels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a rendomised controlled trial. Lancet. 2003;361: 449-56.
25. Szafranski W, Cukier A, Ramírez A, Menga G, Sansores R, Nahabedian S, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:74-81.
26. Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD. Chest. 2004;126: 926-34.
27. Álvarez-Mon M, Miravitlles M, Morera J, Callol L, Álvarez-Sala JL. Treatment with the immunomodulator AM3 (Inmunoferon) improves the health-related quality of life of patients with chronic obstructive pulmonary disease. Chest. 2005;127:1212-8.